Inhaled corticosteroids can reduce osteoporosis in female patients with COPD

Shih-Feng Liu¹–³
Ho-Chang Kuo¹,²,⁴
Guan-Heng Liu⁵
Shu-Chen Ho⁴
Huang-Chih Chang¹,³
Hung-Tu Huang⁶
Yu-Mu Chen¹
Kuo-Tung Huang¹,³
Kuan-Yi Chen²
Wen-Feng Fang¹–³
Meng-Chih Lin¹–³

¹Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, ²Department of Respiratory Therapy, Kaohsiung Chang Gung Memorial Hospital, ³Chang Gung University College of Medicine, ⁴Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, ⁵Li-Chih Valuable School, ⁶Department of Anatomy, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, Republic of China

Correspondence: Meng-Chih Lin
Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Kaohsiung Chang Gung Memorial Hospital, No 123, Ta-Pei Road, Niaosong District, Kaohsiung 833, Taiwan, Republic of China
Tel +886 7 731 7123 ext 8199
Fax +886 7 732 24942
Email mengchih@adm.cgmh.org.tw

Ho-Chang Kuo
Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, No 123, Ta-Pei Road, Niaosong District, Kaohsiung 833, Taiwan, Republic of China
Tel +886 7 731 7123 ext 8802
Fax +886 7 733 8009
Email erickuo48@yahoo.com.tw

Background: Whether the use of inhaled corticosteroids (ICSs) in patients with COPD can protect from osteoporosis remains undetermined. The aim of this study is to assess the incidence of osteoporosis in patients with COPD with ICS use and without.

Patients and methods: This is a retrospective cohort and population-based study in which we extracted newly diagnosed female patients with COPD between 1997 and 2009 from Taiwan’s National Health Insurance (TNHI) database between 1996 and 2011 (International Classification of Diseases, Ninth Revision – Clinical Modification [ICD-9-CM] 491, 492, 496). The patients with COPD were defined by the presence of two or more diagnostic codes for COPD within 12 months on either inpatient or outpatient service claims submitted to TNHI. Patients were excluded if they were younger than 40 years or if osteoporosis had been diagnosed prior to the diagnosis of COPD and cases of asthma (ICD-9 CM code 493.X) before the index date. These enrolled patients were followed up till 2011, and the incidence of osteoporosis was determined. The Cox proportional hazards regression model was also used to estimate hazard ratios (HRs) for incidences of lung cancer.

Results: Totally, 10,723 patients with COPD, including ICS users (n=812) and nonusers (n=9,911), were enrolled. The incidence rate of osteoporosis per 100,000 person years is 4,395 in nonusers and 2,709 in ICS users (HR: 0.73, 95% confidence interval [CI]: 0.63–0.84). The higher ICS dose is associated with lower risk of osteoporosis (0 mg to ≤20 mg, HR: 0.84, 95% CI: 0.69–1.04; >20 mg to ≤60 mg, HR: 0.78, 95% CI: 0.59–1.04; and >60 mg, HR: 0.72, 95% CI: 0.55–0.96; P for trend =0.0023) after adjusting for age, income, and medications. The cumulative osteoporosis probability significantly decreased among the ICS users when compared with the nonusers (P<0.001).

Conclusion: Female patients with COPD using ICS have a dose–response protective effect for osteoporosis.

Keywords: inhaled corticosteroids, COPD, osteoporosis

Introduction

COPD with persistent airflow limitation is usually progressive and is associated with an enhanced chronic inflammatory response in the airways and the lung due to the inhalation of noxious particles or gases.¹ Due to persistent low-grade inflammation in systemic circulation and the same risk factors, COPD often coexists with comorbidities.²–⁷ Osteoporosis is a major comorbidity in COPD associated with poor health status and prognosis.⁷,⁸ This risk of comorbid osteoporosis can be increased by low-grade systemic inflammation or the sequelae of COPD, such as poor nutrition, reduced physical activity, and the use of systemic corticosteroids and tobacco smoking. In addition, older age, menopause, and female sex are the other risk factors for osteoporosis.⁹–¹¹
Inhaled corticosteroids (ICSs) are commonly used for the treatment of chronic COPD. In 2014, updated Global initiative for chronic Obstructive Lung Disease (GOLD) guidelines also recommended ICSs in group C and D patients, although the long-term safety of ICSs has not been established and the adverse effects of long-term use of systemic glucocorticosteroids are documented as involving loss of bone mineral density. The efficacy and side effects of ICSs on bone metabolism in asthma are dependent on the dose and type of corticosteroid, but whether this is also found in COPD is undetermined. Long-term treatment with inhaled triamcinolone was associated with increased loss of bone mass in the Lung Health Study II. However, this was not seen in the patients with COPD for inhaled budesonide in the EUROSCOP trial or for inhaled 500 µg bid (twice per day) fluticasone propionate alone or in combination with salmeterol treatment over a 3-year period in the TORCH trial. Two systematic reviews have concluded that long-term ICS use has not been proven to have a significant impact on bone mineral density. Therefore, to date, this issue of the effect of ICSs on bone metabolism in patients with COPD remains controversial.

Taiwan’s National Health Insurance (TNHI) database can provide a larger population and longer follow-up duration than previous studies. We used this database to conduct a retrospective analysis about the incidence of osteoporosis in patients with COPD with ICS use and without.

 Patients and methods

Ethics statement
The study was approved by the Chang-Gung Memorial Hospital review board (IRB #102-0364B), and the requirement of informed consent was waived due to the fact that personal information had already been deidentified in the National Health Insurance (NHI) Research Database.

Data source
The NHI Program, which provides compulsory universal health insurance, was implemented on March 1, 1995, in Taiwan. Under the NHI, 98% of the island’s population receives all forms of health-care services including outpatient services, inpatient care, Chinese medicine, dental care, childbirth services, physical therapy, preventive health care, home care, and rehabilitation for chronic mental illness. Most medical providers (93%) were under contract with the Bureau of NHI (BNHI), and those not under contract provide fewer health services. More than 96% of the population with insurance coverage through the NHI utilized health services at least one time at contracted medical institutions. From the population of all reimbursement claim records under the single-payer system and using a systematic sampling method, the National Health Research Institute (NHRI) of Taiwan randomly sampled a representative panel database of 1,000,000 subjects in 2,000 designed for research purposes. The NHRI reported that there were no statistically significant differences in the age, sex, and health-care costs between the sample group and all enrollees as noted in our previous report.

Data in an electronic format on daily clinic visits or hospital admissions can be obtained for each contracted medical institution. For reimbursement, all medical institutions must submit their claims for billable medical services on a standardized electronic format, which includes data elements such as the date of admission and discharge, patient identification number, sex, date of birth, and the International Classification of Diseases, Ninth Revision – Clinical Modification (ICD-9-CM) diagnostic code for each admission. Therefore, the information from the NHI database appears to be sufficiently complete, reliable, and accurate for use in epidemiological studies.

Design and study participants
Females are much more likely to develop osteoporosis than males. In Taiwan, smoking prevalence is much lower in females when compared with males. The ratio of male to female smoking rates was 10.9:1 among adults (46.8%/4.3%). Approximately 15%–20% of these female smokers may develop COPD, thus tobacco consumption confounding the incidence of osteoporosis related to ICSs in Taiwanese females is very limited. Additionally, data about tobacco consumption and second-hand exposure cannot be obtained from our BNHI records. Therefore, to decrease the interference of sex and tobacco exposure in the incidence of osteoporosis, we decided to select only female patients in this study. For the cohort, we identified an exposed study cohort from the database consisting of newly diagnosed female patients with COPD (n=25,404, ICD-9-CM 491, 492, 496) from 1996 to 2011. Patients were excluded if they were younger than 40 years or if osteoporosis had been diagnosed prior to the diagnosis of COPD and cases of asthma (ICD-9 CM code 493.X) before the index date. The index date for each participant was the first COPD diagnosis date. Ultimately, in total, 10,723 patients with COPD were included in the cohort study group as shown in the flowchart of Figure 1. The income and age of the patients and use of medications (estrogen, oral steroid, long-acting beta-agonist [LABA], long-acting muscarinic antagonist [LAMA], and short-acting beta-agonist [SABA]) were also included in this study.
The ICSs analyzed in this study included fluticasone propionate and budesonide. Information on ICS exposure was extracted from the prescription database. We defined ICS users as those with at least one prescription of ICSs between the diagnosis of osteoporosis (ICD-9 CM code 733.X) and the index date. The date of prescription, the daily dose, and the number of days supplied were identified, and cumulative doses (mg) were calculated. ICSs were approved in Taiwan in June 2001 and included in the listing of NHI drug reimbursement in February 2002.

Osteoporosis outcome and follow-up

The index date for each participant was the first COPD diagnosis date. We identified the study end point as the first diagnosis of osteoporosis from outpatient claims or hospitalization records from 1997 to 2011. All the study participants were followed from the index date to end point occurrence, withdrawal from the database, or the end of 2011, whichever date came first.

Statistics

The person-years of follow-up for each case were calculated from the date of diagnosed COPD to the date of death, diagnosis of osteoporosis date, or December 31, 2011. Incident rates were calculated by dividing the case number from osteoporosis by the number of person-years of follow-up. Cox proportional hazard regression models adjusting for all potential confounders was used to estimate the relative magnitude of risk in relation to the use of ICSs. The participants were divided into three ICS exposure categories: nonusers, users of doses equal to or less than the median, and users of doses greater than the median based on the distribution of use among all cases of ICS users. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated using patients with no exposure as reference. Analyses were performed using the SAS statistical package (Version 9.3; SAS Institute Inc., Cary, NC, USA). All statistical tests were two sided. A $P$-value $<0.05$ was considered statistically significant.

Results

Patients’ characteristics

Totally, 10,723 patients with COPD, including ICS users (n=812) and nonusers (n=9,911), were enrolled in this study. Demographic characteristics of all patients are listed in Table 1. Among this population, 6,365 patients (59.36%) were older than 60 years and 460 of these patients were ICS users; 5,997 patients (55.93%) had an income of $15,840 New Taiwan Dollars (NTD) per month and 476 of these patients were ICS users; and 7,044 patients (65.69%) had hypertension and 612 of these patients were ICS users.

Variable risk factors associated with osteoporosis

Table 2 presents the incidence rate per 100,000 person-years in the patients with osteoporosis by age, income, and medication. Table 3 presents the crude HR of osteoporosis incidence rate per 100,000 person-years in different variables. Being elderly is associated with a higher risk for osteoporosis ($\geq 40$ to $< 50$, HR: 1; $\geq 50$ to $< 60$, HR: 1.85 [95% CI: 1.63–2.10]; $\geq 60$, HR: 2.22 [95% CI: 1.99–2.47]). The relationship between the income and osteoporosis risk is as follows: $< 15,840$, HR: 1; $\geq 15,840$ to $< 21,900$, HR: 0.8 (95% CI: 0.71–0.89); $\geq 21,900$, HR: 0.7 (95% CI: 0.63–0.79).
to 34,800, HR: 1.08 (95% CI: 0.99–1.17); ≥34,800, HR: 0.62 (95% CI: 0.53–0.72). The incidence rate of osteoporosis per 100,000 person-years is 4,395.00 among ICS nonusers and 2,709.71 among ICS users (ICS nonusers HR: 1; ICS users HR: 0.64 [95% CI: 0.56–0.74]). Other medications such as LABA, LAMA, and SABA were associated with lower risk of osteoporosis. Oral steroid and estrogen were associated with higher risk of osteoporosis.

Independent protective effects of ICSs on osteoporosis in patients with COPD

After adjusting for age, income, and use of medications (estrogen, oral steroid, LABA, LAMA, and SABA), the higher ICS accumulative dose is associated with a lower risk of osteoporosis (0 mg to ≤20 mg, HR: 0.84, 95% CI: 0.69–1.04; >20 mg to ≤60 mg, HR: 0.78, 95% CI: 0.59–1.04; >60 mg, HR: 0.72, 95% CI: 0.55–0.96; P for trend = 0.0023; Table 4). The cumulative osteoporosis

### Table 1 Demographic characteristics of patients in the cohort

| Variables | ICS use | Total |
|-----------|---------|-------|
|           | Yes     | No    |       |
|           | n  | %    | n  | %    | n  | %    |
| Age (years) |       |       |     |       |     |       |
| ≥40 to <50 | 161 | 19.83 | 1,988 | 20.06 | 2,149 | 20.04 |
| 50 to <60  | 191 | 23.52 | 2,018 | 20.36 | 2,209 | 20.60 |
| ≥60        | 460 | 56.65 | 5,905 | 59.58 | 6,365 | 59.36 |
| Income (NTD) |       |       |     |       |     |       |
| <15,840    | 476 | 58.62 | 5,251 | 55.71 | 5,727 | 55.93 |
| ≥15,840 to <21,900 | 80 | 9.85 | 1,203 | 12.14 | 1,283 | 11.96 |
| ≥21,900 to <34,800 | 183 | 22.54 | 2,337 | 23.58 | 2,520 | 23.50 |
| ≥34,800    | 73  | 8.99  | 850  | 8.58  | 923  | 8.61  |
| Baseline comorbidities |       |       |     |       |     |       |
| Tuberculosis | 94  | 11.58 | 566  | 5.71  | 660  | 6.15  |
| Bacterial pneumonia | 104 | 12.81 | 560  | 5.65  | 664  | 6.19  |
| Bronchiectasis | 152 | 18.72 | 730  | 7.37  | 882  | 8.23  |
| Pulmonary fibrosis | 24  | 2.96  | 65   | 0.66  | 89   | 0.83  |
| Hypertension | 612 | 75.37 | 6,432 | 64.90 | 7,044 | 65.69 |
| Diabetes mellitus | 350 | 43.23 | 3,600 | 36.32 | 3,951 | 36.85 |

**Abbreviations:** ICS, inhaled corticosteroids; nTD, New Taiwan Dollars.

### Table 2 Numbers of patients with osteoporosis and the incident rate per 100,000 person-years

| Variables | No of patients | No of person-years | No of patients with osteoporosis | Incident rate (per 100,000 person-years) |
|-----------|----------------|--------------------|----------------------------------|-----------------------------------------|
| Age (years) |       |       |       |                                   |                                         |
| ≥40 to <50 | 2,149 | 17,276.56 | 389 | 2,251.61 |
| 50 to <60  | 2,209 | 15,719.91 | 668 | 4,249.39 |
| ≥60        | 6,365 | 46,833.45 | 2,329 | 4,972.94 |
| Income (NTD) |       |       |     |                                   |                                         |
| <15,840    | 5,997 | 4,4751.27 | 1,973 | 4,408.81 |
| ≥15,840 to <21,900 | 1,283 | 1,0757.61 | 361 | 3,355.76 |
| ≥21,900 to <34,800 | 2,520 | 1,7577.67 | 863 | 4,909.64 |
| ≥34,800    | 923  | 6,743.36 | 189 | 2,802.76 |
| Medication |       |       |     |                                   |                                         |
| Estrogen   |       |       |     |                                   |                                         |
| No         | 9,407 | 70,133.46 | 2,784 | 3,969.57 |
| Yes        | 1,316 | 9,696.46 | 602 | 6,208.45 |
| LABA       |       |       |     |                                   |                                         |
| No         | 10,360 | 76,744.50 | 3,328 | 4,336.47 |
| Yes        | 363  | 3,085.42 | 58  | 1,879.81 |
| LAMA       |       |       |     |                                   |                                         |
| No         | 10,659 | 79,289.20 | 3,381 | 4,264.14 |
| Yes        | 64   | 540.72  | 5   | 924.69 |
| Oral steroid |       |       |     |                                   |                                         |
| Yes        | 652  | 45,110.75 | 2,217 | 4,914.57 |
| No         | 420  | 34,719.17 | 1,169 | 3,367.02 |
| SABA       |       |       |     |                                   |                                         |
| No         | 9,637 | 70,356.94 | 3,089 | 4,390.47 |
| Yes        | 1,086 | 9,472.98 | 297 | 3,135.23 |
| ICS use    |       |       |     |                                   |                                         |
| No ICS use | 9,911 | 72,559.76 | 3,189 | 4,395.00 |
| Any ICS use | 812 | 7,270.16 | 197 | 2,709.71 |
| >0 mg to ≤20 mg | 358 | 3,016.27 | 93 | 3,083.28 |
| >20 mg to ≤60 mg | 208 | 1,900.12 | 49 | 2,578.79 |
| >60 mg     | 246  | 2,353.77 | 55  | 2,336.68 |

**Abbreviations:** ICS, inhaled corticosteroids; nTD, New Taiwan Dollars; SABA, short-acting beta-agonist; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist.
Discussion

Our study demonstrated that ICS users exhibit an association with a lower risk for osteoporosis and a dose–effect relationship. How can ICSs reduce osteoporosis in patients with COPD? Our explanations are as follows: first, regular treatment with ICSs can reduce systemic inflammation in COPD. There is a growing body of data to support this and it provides a plausible mechanism for clinical benefits with regard to COPD. COPD is primarily a pulmonary disease, but it has various extrapulmonary manifestations, such as deconditioning, exercise intolerance, skeletal muscle dysfunction, osteoporosis, metabolic impact, anxiety and depression, cardiovascular disease, and mortality. The comorbidities in COPD are associated with a result of “overspill” of inflammatory mediators from the lungs. Many circulating inflammatory mediators are elevated in stable COPD and during exacerbations. C-reactive protein (CRP), tumor necrosis factor-alpha, and interleukin-6 (IL-6) are the known markers of systemic inflammation and are associated with osteoporosis. The patients with COPD with ICSs withdrawn show CRP-level reductions when retreated with ICSs, whereas patients retreated with placebo do not. The effect of inhaled budesonide can decrease neutrophils, IL-6, tumor necrosis factor-alpha, and IL-8 levels in bronchoalveolar lavage sample in patients with COPD. Biopsies of the airways of COPD smokers with inhaled fluticasone showed decreased CD8/CD4 ratios and decreased subendothelial mast cells when compared

Table 3 The crude HR of osteoporosis incident rate per 100,000 person-years in variable categories

| Variables          | Crude HR (95% CI) |
|--------------------|------------------|
| Age (years)        |                  |
| ≥40 to <50         | 1.00             |
| ≥50 to <60         | 1.85 (1.63–2.10) |
| ≥60                | 2.22 (1.99–2.47) |
| Income (NTD)       |                  |
| <15,840            | 1.00             |
| ≥15,840 to <21,900 | 0.80 (0.71–0.89) |
| ≥21,900 to <34,800 | 1.08 (0.99–1.17) |
| ≥34,800            | 0.62 (0.53–0.72) |
| Medication         |                  |
| Estrogen           |                  |
| No                 | 1.00             |
| Yes                | 1.59 (1.46–1.74) |
| LABA               |                  |
| No                 | 1.00             |
| Yes                | 0.44 (0.34–0.57) |
| LAMA               |                  |
| No                 | 1.00             |
| Yes                | 0.22 (0.09–0.53) |
| Oral steroid       |                  |
| Yes                | 1.00             |
| No                 | 0.70 (0.65–0.75) |
| SABA               |                  |
| No                 | 1.00             |
| Yes                | 0.74 (0.66–0.84) |
| ICS use            |                  |
| No ICS use         | 1.00             |
| Any ICS use        |                  |
| >0 mg to ≤20 mg    | 0.64 (0.56–0.74) |
| >20 mg to ≤60 mg   | 0.72 (0.58–0.88) |
| >60 mg             | 0.61 (0.46–0.81) |
| P for trend        | = 0.0001         |

Abbreviations: CI, confidence interval; HR, hazard ratio; ICS, inhaled corticosteroids; NTD, New Taiwan Dollars; SABA, short-acting beta-agonist; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist.

Table 4 The HR of osteoporosis incident rate per 100,000 person-years in variable ICS dose

| ICS dose            | Adjusted HR (95% CI) | P for trend |
|---------------------|----------------------|-------------|
| No ICS use          | 1.00                 |             |
| Any ICS use         |                      |             |
| >0 mg to ≤20 mg     | 0.80 (0.68–0.92)     |             |
| >20 mg to ≤60 mg    | 0.84 (0.69–1.04)     |             |
| >60 mg              | 0.78 (0.59–1.04)     |             |
| P for trend         | 0.0023               |             |

Note: Adjusted for age, income, and use of medications (estrogen, oral steroid, LABA, LAMA, and SABA).

Abbreviations: CI, confidence interval; HR, hazard ratio; ICS, inhaled corticosteroid; SABA, short-acting beta-agonist; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist.

Figure 2 The cumulative osteoporosis probability among the ICS users compared with nonusers.

Note: The cumulative osteoporosis probability significantly decreased among the ICS users compared with nonusers (P<0.001).

Abbreviation: ICS, inhaled corticosteroid.
with placebo patients.24 The patients with COPD with inhaled fluticasone had fewer COPD exacerbations, which indicate that decreased airway inflammation plays a role in the beneficial effect of ICSs.28 Decreased airway and lung inflammation by ICSs will decrease the overspill of inflammatory mediators to circulation. Additionally, histone deacetylases in the presence of corticosteroids for patients with COPD downregulate the transcription of inflammatory cytokines.29 A recent study demonstrated that long-term administration of ICSs decelerates the annual bone mass loss in bronchitic patients, possibly by reducing both pulmonary and systemic inflammation caused by COPD.30 Second, regular use of ICSs can reduce the frequency of exacerbations in patients with COPD.30–33 Withdrawal from treatment with ICSs may lead to exacerbations in some patients.34 Decreased frequencies of acute exacerbation in patients with COPD can reduce osteoporosis. Kiyokawa et al35 demonstrated that COPD exacerbations were independently associated with osteoporosis progression in a longitudinal study and recommended that osteoporosis evaluation in patients with COPD with frequent exacerbations. The frequency of acute exacerbation is related to bone metabolism markers. The frequency of acute exacerbation within the past 1 year and 25-OH vitamin D level are the independent risk factors for β-C-telopeptides of type I collagen; the frequency of acute exacerbation is the only independent risk factor for N-terminal midmolecule fragment osteocalcin.36 Third, regular treatment with ICSs improves symptoms, lung function, and quality of life in patients with COPD, which can increase exercise tolerance and decrease immobility-induced bone loss. In combination with drugs treatment, patients with COPD appear to benefit from rehabilitation and maintenance of physical activities.37 Although there is an association between ICSs and osteoporosis in pharmacoepidemiological studies, these studies have not fully taken COPD severity or exacerbations and their treatment into consideration. In fact, higher exacerbation rates are associated with a faster loss of lung function38 and greater worsening of health status.39 Hospitalization for a COPD exacerbation is associated with a poor prognosis.40 Long-term treatment with ICSs and long-acting bronchodilators improves symptoms, lung function, and quality of life and reduces the frequency of exacerbations in patients with COPD with an FEV1 < 60% predicted.30–33 Because of there being documented adverse biological effects with regard to systemic or oral steroids, including adrenal suppression, loss of bone mass density, and risk of fracture, ICSs should be suggested in selected patients with COPD with frequent exacerbations in order to reduce systemic or oral steroids usage during exacerbation attacks.

In addition, there are many rationales for clinicians to use ICSs in patients with COPD. ICSs allow the delivery of a drug directly to the target organ and the ability to use lower cumulative doses of corticosteroid and to avoid systemic absorption. In fact, inhaled fluticasone propionate or budesonide used for the treatment of COPD is absorbed through the gastrointestinal tract and first-pass metabolism of the liver, thus a complete absence of systemic absorption of ICSs is minimal. Therefore, the vast majority of systemically absorbed ICSs occurs through the lungs. Less systemic absorption occurs in patients with diseased lung than in patients with normal lung function with fluticasone use.41 The average age of female menopause is 49.5 years in Taiwan,42 and this loss of estrogens accelerates bone loss for a period ranging from 5 years to 8 years. The distribution and effect of menopause vary in the group of 50–60 year-olds. It is well established that estrogen replacement during menopause protects bone mass.42,43 Current data showed that estrogen replacement was associated with osteoporosis. The possible explanation is because estrogen replacement was prescribed in menopausal females, and it was not prescribed in nonmenopausal patients with COPD. In addition, oral corticosteroid plays an important role in osteoporosis. Bronchodilators such as SABA, LABA, and LAMA can decrease the frequencies of acute exacerbation and thus associate with lower incidences of osteoporosis. Therefore, when we adjust for these related important factors for osteoporosis, the results still prove that ICS is an independent factor for osteoporosis in female patients with COPD.

Limitations of the study

There are a number of important limitations that should be highlighted. First, we used ICD-9 diagnosis to enroll the patients, thus we were unable to confirm COPD diagnoses by spirometry and to differentiate severity by FEV1, either. Osteoporosis may be related to COPD severity. However, there exist many debates on the evaluations of COPD severity. The updated guidelines indicate that the evaluation of COPD severity needs multidimensional approach, such as GOLD 2014 guidelines using the Modified British Medical Research Council (mMRC) scale, COPD Assessment Test (CAT) score, forced expiratory volume in one second (FEV1), and the frequencies of acute exacerbation and hospitalization to divide ABCD groups. Body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) score,
Acknowledgments

This study was supported by a grant from the National Science Council, Taiwan (NSC 102-2314-B-182-053-MY3) and a grant from the Chang Gung Memorial Hospital (CMRPG8C1081 and CMRPG8B0211).

Disclosure

The authors report no conflicts of interest in this work.

References

1. The Global Initiative for Chronic Obstructive Lung Disease: GOLD [homepage on the Internet]. Available from: http://www.goldcopd.com. Accessed May 4, 2016.
2. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. *Eur Respir J*. 2009;33(5):1165–1185.
3. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. *Eur Respir J*. 2008;32(4):962–969.
4. Sín DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. *Eur Respir J*. 2006;28(6):1245–1257.
5. Almagro P, Cabrera FJ, Diez J, et al; Working Group on COPD, Spanish Society of Internal Medicine. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de medicina interna (ESMI) study. *Chest*. 2012;142(5):1126–1133.
6. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of “overspill” of inflammatory mediators from the lungs? Review of the evidence. *Thorax*. 2010;65(10):930–936.
7. Fabbri LM, Luppi F, Beghè B, Rabef KF. Complex chronic comorbidities of COPD. *Eur Respir J*. 2008;31(1):204–212.
8. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. *Chest*. 2005;128(4):2099–2107.
9. Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. *BMJ*. 1997;315(7112):841–846.
10. Biskobing DM. COPD and osteoporosis. *Chest*. 2002;121(2):609–620.
11. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. *N Engl J Med*. 1995;332(12):767–773.
12. Dubois EF, Röder E, Dekhuizen PN, Zwinderman AE, Schweitzer DH. Dual energy X-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens. *Chest*. 2002;121(5):1456–1465.
13. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. *Clin Microbiol Rev*. 1996;9(4):532–562.
14. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. *N Engl J Med*. 2000;343(26):1902–1909.
15. Pauwels RA, Löfdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. *N Engl J Med*. 1999;340(25):1948–1953.
16. Ferguson GT, Calverley PM, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. *Chest*. 2009;136(6):1456–1465.
17. Halpern MT, Schnier JK, Van Kerkhove MD, Watkins M, Kalberg CJ. Impact of long-term inhaled corticosteroid therapy on bone mineral density: results of a meta-analysis. *Ann Allergy Asthma Immunol*. 2004;92:201–207. Quiz 207–208, 267.
18. Jones A, Fay JK, Burr M, Stone M, Hood K, Roberts G. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2002;(1):CD003537.

19. Kuo HC, Chang WC, Yang KD, et al. Kawasaki disease and subsequent risk of allergic diseases: a population-based matched cohort study. *BMC Pediatr.* 2013;13:38.

20. Mayo Clinic [webpage on the Internet]. Risk Factors. Available from: http://www.mayoclinic.org/diseases-conditions/osteoarthritis/basics/risk-factors/con-20019924. Accessed May 4, 2016.

21. Wen CP, Levy DT, Cheng TY, Hsu CC, Tsai SP. Smoking behaviour in Taiwan, 2001. *Tob Control.* 2005;14(suppl 1):i51–i55.

22. Black S, Kushner I, Samols D. C-reactive protein. *J Biol Chem.* 2004; 279(47):48487–48490.

23. Liang B, Feng Y. The association of low bone mineral density with systemic inflammation in clinically stable COPD. *Endocrine.* 2012;42(1):190–195.

24. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2004;170(7):760–765.

25. Ozol D, Aysan T, Solak ZA, Mogulkoc N, Veral A, Sebik F. The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. *Respir Med.* 2005;99(12):1494–1500.

26. Crisafulli E, Menéndez R, Huerta A, et al. Systemic inflammatory pattern of patients with community-acquired pneumonia with and without COPD. *Chest.* 2013;143(4):1009–1017.

27. Ko FW, Leung TF, Wong GW, et al. Measurement of tumor necrosis factor-alpha, leukotriene B4, and interleukin 8 in the exhaled breath condensate in patients with acute exacerbations of chronic obstructive pulmonary disease. *Respirology.* 2013;18(1):147–153.

28. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. C-reactive protein. *J Biol Chem.* 2004; 279(47):48487–48490.

29. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity and chronic obstructive pulmonary disease exacerbations. *Eur Respir J.* 2003;21(1):68–73.

30. Mathioudakis AG, Amanetopoulou SG, Gialmanidis IP, et al. Impact of long-term treatment with low-dose inhaled corticosteroids on the bone mineral density of chronic obstructive pulmonary disease patients: aggravating or beneficial? *Respirology.* 2013;18(1):147–153.

31. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. *Eur Respir J.* 2003;21(1):74–81.

32. Jones PW, Willits LR, Burge PS, Calverley PM. Inhaled Steroids in Obstructive Lung Disease in Europe study investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. *Eur Respir J.* 2003;21(1):68–73.

33. Calverley PM, Anderson JA, Celli B, et al; TORCH investigators. Salbutamol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med.* 2007;356(8):775–789.

34. van der Valk P, Momminkhof E, van der Palen J, Ziehuijs G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. *Am J Respir Crit Care Med.* 2002;166(10):1358–1363.

35. Kiyokawa H, Muro S, Oguma T, et al. Impact of COPD exacerbations on osteoporosis assessed by chest CT scan. *COPD.* 2012;9(3):235–242.

36. Xiaomei W, Hang X, Lingling L, Xuejun L. Bone metabolism status and associated risk factors in elderly patients with chronic obstructive pulmonary disease (COPD). *Cell Biochem Biophys.* 2014;70(1):129–134.

37. Berry MJ, Rejeski WJ, Adair NE, Zaccaro D. Exercise rehabilitation and chronic obstructive pulmonary disease stage. *Am J Respir Crit Care Med.* 1999;160(4):1248–1253.

38. Soler-Cataluña JJ, Martinez-Garcia MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. *Thorax.* 2005;60(11):925–931.

39. Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K. Safety of inhaled corticosteroids. *Proc Am Thorac Soc.* 2004;1(3):171–175.

40. Chow SN, Huang CC, Lee YT. Demographic characteristics and medical aspects of menopausal women in Taiwan. *J Formos Med Assoc.* 1997;96(10):806–811.

41. Isaacs AJ, Britton AR, McPherson K. Utilisation of hormone replacement therapy by women doctors. *BMJ.* 1995;311(7017):1399–1401.